Skip to content
MARKETS / NASDAQ / ALEC
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP

Alector, Inc. ALEC

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$21.0M
▼ 79.1% YoY
$-142.9M
$-184.1M
In brief

What this company does

Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. A key component of our strategy is the development and application of our Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) delivery technology designed to improve central nervous system exposure across multiple therapeutic modalities. We were initially formed as a limited liability company in Delaware in May 2013 under the name Alector LLC and completed our restructuring to a Delaware corporation in October 2017 under the name Alector, Inc. Our principal executive offices are located at 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080.

Written from the business description in Alector, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth
USD 21.0M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 21.0 · Net income -142.9
80M160M-80M-160M201720182019202020212022202320242025
Compound annual growth
−46.0%
−0.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −0.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−679 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -741.3% · Net -679.2%
-500%-1000%201720182019202020212022202320242025
ROE
FY2025 · ROE -181.6%
-100%-200%201720182019202020212022202320242025

Each USD of equity lost 182 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -184.1
100M200M-80M-160M201720182019202020212022202320242025

Total assetsUSD 293.2M
EquityUSD 30.6M
CashUSD 65.8M
Gross debtUSD 9.7M
Net debtUSD -56.1M
Current ratio3.83×

The company holds more cash than debt.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B0.00.10.10.10.20.00.00.00.0
Operating income $B−0.2−0.1−0.2−0.1−0.0−0.2−0.1−0.1−0.0
EBITDA $B·········
Income tax $B0.00.00.00.00.00.00.0··
Net income $B−0.1−0.1−0.1−0.1−0.0−0.2−0.1−0.1−0.0
Free cash flow $B−0.2−0.2−0.2−0.00.3−0.2−0.10.1−0.0
EPS, diluted $−1.39−1.23−1.56−1.62−0.45−2.45−1.71−4.62−3.55
Dividend / sh $·········
Payout %·········
ROE %−181.6−91.2−74.8−51.8−12.8−82.3−216.5··
Shares out B0.110.100.080.080.080.080.070.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 42 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image